| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:Izilendustat hydrochloride
CAS:1303513-80-5
Package:25mg/RMB 14900;100mg/RMB 24625;50mg/RMB 19420
|
Izilendustat hydrochloride manufacturers
|
| | Izilendustat hydrochloride Basic information |
| Product Name: | Izilendustat hydrochloride | | Synonyms: | Izilendustat hydrochloride;1-Piperazinecarboxylic acid, 4-[[1-[(4-chlorophenyl)methyl]-1,2-dihydro-3-hydroxy-2-oxo-4-pyridinyl]methyl]-, 1,1-dimethylethyl ester, hydrochloride (1:1) | | CAS: | 1303513-80-5 | | MF: | | | MW: | 470.39 | | EINECS: | | | Product Categories: | | | Mol File: | 1303513-80-5.mol |  |
| | Izilendustat hydrochloride Chemical Properties |
| | Izilendustat hydrochloride Usage And Synthesis |
| Uses | Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase which stabilizes hypoxia inducible factor- 1 alpha (HIF- lα), as well as hypoxia inducible factor-2 (HIF-2). Izilendustat (hydrochloride) has the potential for the research of HIF- lα related diseases including Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, anemia, colitis, and other inflammatory bowel diseases (extracted from patent WO2011057115A1/WO2011057112A1/WO2011057121A1)[1][2][3]. | | References | [1] Joseph H, et al. Prolyl hydroxylase inhibitors. Patent WO2011057115A1.
[2] Robert Shalwitz, et al. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha. Patent WO2011057112A1.
[3] Joseph H, et al. Compositions and methods for treating colitis. Patent WO2011057121A1. |
| | Izilendustat hydrochloride Preparation Products And Raw materials |
|